Deals

Celltrion unveils its agreement with the PBM Express Scripts that will place its Zymfentra subcutaneous infliximab on its preferred formulary after alluding to the deal in an earlier notice. 

Teva and Alvotech have confirmed deductions that it is their recently-approved 100mg/ml adalimumab biosimilar that will be used by Cigna’s Evernorth as part of a recently announced private-label deal involving Evernorth’s Quallent Pharmaceuticals.

Sandoz has secured a launch date for its newly-approved US denosumab biosimilars, settling patent litigation with Prolia/Xgeva originator Amgen.

Hikma will look to guarantee US generic competition to the powerful opioid brand Nucynta, albeit in the form of an authorized generic, as questions swirl over the appetite of at least one ANDA filer to compete on an equal footing, per the terms of a patent-litigation settlement deal.

India’s Biocon Limited has struck an exclusive deal for a generic version of semaglutide in Brazil with local player Biomm. And a recent court ruling means that launch could come sooner rather than later for the Ozempic rival.

It’s been a year since Biogen made it clear that it was ready to put its biosimilars business on the market. But despite signaling interest in the unit from multiple potential suitors over the past 12 months, the firm says it hasn’t yet received any “acceptable” offers, and may retain it after all.

After getting off to a slow start last year, US biosimilar rivals to Humira are beginning to gain more traction. Sandoz is increasing its share on a weekly basis, Alvotech and Teva have struck a deal for their newly-approved interchangeable 100mg/ml biosimilar, and the latest market data shows biosimilars capturing twice as much of the market in Q1 as in Q4 2023.

Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.

Characterizing biosimilars as a global movement towards the democratization of medicine, Formycon CEO Stefan Glombitza speaks to Generics Bulletin in detail about the company’s recent deals, launches and key pipeline assets, in the first part of an exclusive two-part interview.

The rumor mill is heating up on Stada’s potential sale by its owners, Bain Capital and Cinven, after seven years at the helm.

With a clear angle of increasing access to medicines in India, Dr Reddy’s signature landed on three branded deals with pharma firms, bringing more vaccines, cardiovascular and resuscitative drugs to the country.

Teva continues to find comfort with an ally on biosimilar development, striking a deal with the Fresenius-Kabi-backed mAbxience for an undisclosed oncology biosimilar.

Teva has struck a $150m strategic development funding agreement with Abingworth and a clinical collaboration agreement with Launch Therapeutics to accelerate development of a dual-action asthma rescue inhaler.

Apotex has taken a major step to bolster its innovative interests with the acquisition of fellow Canadian firm and specialty branded player Searchlight Pharma.

Ipca Laboratories underlined its commitment to successfully developing quality and affordable biosimilars meeting global standards as it penned a technology transfer agreement with a fellow Indian firm.

Bora Pharmaceuticals has completed its takeover of Upsher-Smith from Sawai, with the acquisition opening up new US opportunities for the Taiwanese company including providing the firm with its first US manufacturing sites.